ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjögrens syndrome-like MRL/lpr mice.
about
Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye diseaseLifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy.Biocompatibility of a synthetic extracellular matrix on immortalized vocal fold fibroblasts in 3-D culture.Effects of a thrombomodulin-derived peptide on monocyte adhesion and intercellular adhesion molecule-1 expression in lipopolysaccharide-induced endothelial cells.Dry eye as a mucosal autoimmune disease.A clinical study of the efficacy of topical corticosteroids on dry eye.Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence.Age-related Defects in Ocular and Nasal Mucosal Immune System and the Immunopathology of Dry Eye DiseaseOcular surface immunity: homeostatic mechanisms and their disruption in dry eye diseaseOcular tropism of respiratory virusesSafety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled StudyDry eye disease: an immune-mediated ocular surface disorder.Interleukin-1 receptor mediates the interplay between CD4+ T cells and ocular resident cells to promote keratinizing squamous metaplasia in Sjögren's syndrome.Elevated percentage of HLA-DR⁺ and ICAM-1⁺ conjunctival epithelial cells in active Graves' orbitopathy.New agents for treating dry eye syndrome.Biologic treatment in Sjögren's syndrome.The role and treatment of inflammation in dry eye disease.Anti-inflammatory effect of hydroxyproline-GQDGLAGPK in desiccation stress-induced experimental dry eye mouse.Lifitegrast for the treatment of dry eye disease in adults.LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye DiseaseLifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye.Use of the Controlled Adverse Environment (CAE) in Clinical Research: A Review.Dry eye syndrome: developments and lifitegrast in perspective.Flow cytometric analysis of HLA-DR antigen in conjunctival epithelial cells of patients with cystic fibrosis.Anti-Inflammatory and Anti-Apoptotic Effects of Acer Palmatum Thumb. Extract, KIOM-2015EW, in a Hyperosmolar-Stress-Induced In Vitro Dry Eye Model.What We Have Learned From Animal Models of Dry Eye.
P2860
Q26746232-611D8A5F-5BE8-4EAE-AA13-C2209FA9BFDDQ33739879-F5DA2EFD-23D1-4277-87C9-69296D11466DQ33903153-2BC1E0D9-901F-44D6-8442-935C91D9AA8BQ34582931-0E953185-1B18-4BA2-8C9B-343CCF895200Q34647761-B5EC4976-47F3-42FB-9D2C-FB047787F965Q34943771-9B6A7F67-7C44-43BC-968D-06417D57C509Q35570541-399E17D1-34A8-417F-B1CD-0516607CCE02Q35773063-E05233CA-FDE8-4DB9-89FA-640A0F7E098EQ35907009-FDCA1123-7EFF-42CD-8A50-F933BA3FAA50Q36667382-498C433E-0048-4C71-93D1-0CCC4D2384B5Q36877000-4D357E4A-A55F-44AE-9DBB-B23BEA79C561Q36916372-11092875-ACE5-4E1B-A0EC-B98111C2E84AQ37050342-1ECDE932-277C-4336-AB0F-8521D1F4EB2DQ37670358-180102CB-B189-412E-B9A8-949C41CE975EQ38058002-3E60E476-0E94-43AC-BFB3-2F1B1290DE3EQ38262453-63A88A56-CFEB-422A-986D-4FBD0C429A8AQ38270449-D0CAAAA3-ED20-4734-906D-1CBCA190222AQ38369119-FF275C4D-CCEF-4008-A67A-35C0DB9228B4Q38608475-04FBB54E-1343-4390-B2D3-CD39F516B963Q39025675-12557E02-A240-45B6-8138-30AD0E475789Q39069560-9813BB27-7113-4239-BC1A-2D0BF4391055Q39730888-F94B3659-FE35-4D6D-B8B2-5AB39B399465Q47100458-DC7778BF-F055-43DA-8F50-DE8B2D17FBBCQ47639135-9A004E38-432A-4F06-82E6-7C5B385A29EFQ50729760-9DD15343-223E-4FE3-B02F-2BA0681715F1Q53081062-98872131-4C3F-4E7B-8078-7FEC6E841629Q53999120-9A9A2CD6-0CA9-4118-8C52-122C4C0DDB4C
P2860
ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjögrens syndrome-like MRL/lpr mice.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
ICAM-1 expression predisposes ...... ns syndrome-like MRL/lpr mice.
@en
ICAM-1 expression predisposes ...... ns syndrome-like MRL/lpr mice.
@nl
type
label
ICAM-1 expression predisposes ...... ns syndrome-like MRL/lpr mice.
@en
ICAM-1 expression predisposes ...... ns syndrome-like MRL/lpr mice.
@nl
prefLabel
ICAM-1 expression predisposes ...... ns syndrome-like MRL/lpr mice.
@en
ICAM-1 expression predisposes ...... ns syndrome-like MRL/lpr mice.
@nl
P2093
P1476
ICAM-1 expression predisposes ...... ns syndrome-like MRL/lpr mice.
@en
P2093
David Tieu
Grant Morgan
Jessica Y Luo
Jianping Gao
Larry A Wheeler
Michael E Stern
Tammy A Schwalb
P304
P356
10.1016/J.EXER.2003.10.024
P577
2004-04-01T00:00:00Z